Janux Therapeutics, Inc. Announces Board Reclassification to Achieve Director Class Balance

Key Highlights from the Report

• Filing Type: 8-K (Current Report)
• Date of Report: April 28, 2026
• Company: Janux Therapeutics, Inc. (NASDAQ: JANX)
• Subject: Reclassification of Board Member to Achieve Balanced Director Classes

Details of the Announcement

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company, has released a Form 8-K announcing a change in the classification of its Board of Directors. The Board has determined that, in order to achieve a more equal balance of membership among its three director classes, one of the current Board members will be reclassified from Class III to Class II.

• Previous Classification: The affected director was serving as a Class III director, with a term expiring at the Company’s 2027 Annual Meeting of Stockholders.
• New Classification: This director will now be in Class II, with a term expiring at the 2026 Annual Meeting of Stockholders.

The company notes that this reclassification is intended solely to create a more balanced allocation of directors among the three classes and does not otherwise change the composition or size of the Board.

What Investors and Shareholders Need to Know

• Governance Structure: The adjustment in director classification may have implications for future governance, particularly around Board continuity and elections at annual meetings. Shareholders should be aware that this move is administrative and not associated with any director resignation or new appointment.
• No Change in Board Membership: There are no resignations, new appointments, or removals. This is a realignment for structural balance, not a change in leadership or strategic direction.
• Potential Share Price Impact: While this announcement does not directly impact the company’s operations, financial performance, or strategic outlook, any changes in Board structure or governance can affect investor sentiment, particularly for those closely tracking leadership stability and governance best practices.
• No Other Compensatory Arrangements: The filing does not announce any new compensatory arrangements, severance, or bonuses that could impact the company’s financials in the short term.

Security Details

• Trading Symbol: JANX
• Exchange: Nasdaq Global Market
• Class of Securities: Common Stock, \$0.001 par value per share

Corporate Information

• Address: 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA 92130
• Phone: (858) 751-4493
• State of Incorporation: Delaware (DE)
• Fiscal Year End: December 31
• SEC File Number: 001-40475
• Employer Identification Number (EIN): 82-2289112

Summary

This filing is primarily administrative, intended to maintain balanced director classes in compliance with best governance practices. It does not reflect any change in company leadership, management, or strategic direction. As such, no immediate price-sensitive events or material operational changes are disclosed. However, investors should always be aware of Board structure changes as part of their ongoing governance monitoring.

Disclaimer: This article is a summary and interpretation of Janux Therapeutics, Inc.’s public SEC filings as of April 28, 2026. It is intended for informational purposes only and does not constitute investment advice. Investors should review the full SEC filings and consult financial professionals before making investment decisions.

View Janux Therapeutics, Inc. Historical chart here